AB2Bio is a biotech company focused on developing “best in class” therapies for severe inflammatory diseases. Inflammation is a natural defense mechanism but when dysregulated and persistent becomes the root cause of severe diseases such as primary HLH, Macrophage Activation Syndrome, Still's Disease and many others.

AB2Bio is developing Tadikinig alfa, an IL18 binding protein (IL18bp), for severe hyperinflammatory conditions such as primary HLH. Tadikinig alfa successfully completed a Phase III trial in Primary HLH and currently progressing to BLA. AB2Bio is harnessing the potential of IL18bp in a series of other hyperinflammatory condition setting thus a new standard of care in those large unmet medical conditions.